The DUSP23 Knockout AGS Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DUSP23 gene in the AGS human gastric adenocarcinoma cell line. This polyclonal knockout pool offers a heterogeneous collection of gene-edited cells, enabling the study of DUSP23 loss-of-function across a broad cellular context without clonal selection biases. The targeted disruption of DUSP23 serves as a valuable tool for investigating the regulatory roles of dual-specificity phosphatases in MAP kinase signaling networks.
The AGS host cell line is an epithelial cell model derived from a patient with gastric adenocarcinoma, widely employed to study gastric cancer biology, including tumorigenic mechanisms, drug response, and epithelial-mesenchymal transitions. As a representative gastric mucosal epithelial line, AGS cells exhibit key oncogenic signaling pathways, rendering them highly relevant for dissecting the molecular underpinnings of adenocarcinoma progression and therapeutic resistance. The CRISPR-edited polyclonal population retains the inherent cellular background of AGS cells while introducing targeted DUSP23 gene disruption.
DUSP23 functions as a dual-specificity phosphatase that negatively regulates MAP kinase signaling by dephosphorylating both phosphotyrosine and phosphothreonine/serine residues on key MAPKs. It directly targets MAPK1/MAPK3 (ERK1/2), MAPK8/MAPK9 (JNK), and MAPK14 (p38), attenuating their kinase activity in response to upstream signals. Growth factors such as EGF and FGF activate receptor tyrosine kinases, leading to sequential activation of the MAPK cascade, which DUSP23 counteracts. DUSP23 interacts with these MAPK substrates and serves as a critical node in feedback regulation, modulating cellular outcomes including proliferation, differentiation, and stress responses.
In the AGS gastric cancer model, ablation of DUSP23 is anticipated to result in sustained or enhanced MAPK pathway activation, providing a unique platform to examine how unchecked ERK, JNK, and p38 signaling influences gastric cancer phenotypes. This model may reveal contributions of DUSP23 to tumor cell proliferation, apoptosis evasion, and adaptive responses to chemotherapeutic agents. Researchers can exploit the DUSP23 knockout AGS polyclonal cells to delineate the phosphatase’s tumor-suppressive or oncogenic roles in the context of gastric adenocarcinoma.
Research applications include detailed analysis of MAPK pathway negative feedback loops, assessment of DUSP23’s impact on gastric cancer cell drug sensitivity, and exploration of phosphatase-targeted therapeutic strategies. Paired with isogenic wild-type AGS controls, the polyclonal knockout population facilitates robust comparative studies using western blotting for phospho-ERK, phospho-JNK, and phospho-p38, RT-qPCR for downstream target gene expression, and functional assays such as MTT/XTT proliferation tests, Annexin V apoptosis assays, and in vitro phosphatase activity measurements; additionally, in vivo xenograft tumor growth experiments can evaluate the role of DUSP23 in tumor progression. For further details, please contact Ascent Research.
